PROPINE
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROPINE is an ophthalmic solution approved in 1980 for treatment of glaucoma and ocular hypertension. The drug is a small-molecule alpha-adrenergic agonist administered as eye drops. It works by reducing intraocular pressure through increased uveoscleral outflow and decreased aqueous humor production.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial team is likely focused on managed decline and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PROPINE offers limited career upside as a mature, LOE-approaching product with zero currently linked job openings. Professionals joining this team should expect a defensive commercial strategy focused on retention and managed decline rather than growth or innovation.
Brand Manager (Ophthalmology)Field Sales Representative
Worked on PROPINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.